1
|
Edwards-Faret G, de Vin F, Slezak M, Gollenbeck L, Karaman R, Shinmyo Y, Batiuk MY, Pando CM, Urschitz J, Rincon MY, Moisyadi S, Schnütgen F, Kawasaki H, Schmucker D, Holt MG. Corrigendum to "A New Technical Approach for Cross-species Examination of Neuronal Wiring and Adult Neuron-glia Functions" [Neuroscience 508 (2023) 40-51]. Neuroscience 2023; 528:140-141. [PMID: 37328143 DOI: 10.1016/j.neuroscience.2023.06.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/18/2023]
Affiliation(s)
- Gabriela Edwards-Faret
- VIB Center for Brain and Disease Research, Herestraat 49, Leuven 3000, Belgium; KU Leuven Department of Neuroscience, Herestraat 49, Leuven 3000, Belgium; Neuronal Wiring Group, Life & Medical Sciences Institute, University of Bonn, Carl-Troll-Straße 31, Bonn D53115, Germany
| | - Filip de Vin
- VIB Center for Brain and Disease Research, Herestraat 49, Leuven 3000, Belgium; KU Leuven Department of Neuroscience, Herestraat 49, Leuven 3000, Belgium
| | - Michal Slezak
- VIB Center for Brain and Disease Research, Herestraat 49, Leuven 3000, Belgium; KU Leuven Department of Neuroscience, Herestraat 49, Leuven 3000, Belgium
| | - Lennart Gollenbeck
- Neuronal Wiring Group, Life & Medical Sciences Institute, University of Bonn, Carl-Troll-Straße 31, Bonn D53115, Germany
| | - Ruçhan Karaman
- VIB Center for Cancer Biology, Herestraat 49, Leuven 3000, Belgium; KU Leuven Department of Oncology, Herestraat 49, Leuven 3000, Belgium
| | - Yohei Shinmyo
- Department of Medical Neuroscience, Graduate School of Medicine, Kanazawa University, Ishikawa 920-1192, Japan
| | - Mykhailo Y Batiuk
- VIB Center for Brain and Disease Research, Herestraat 49, Leuven 3000, Belgium; KU Leuven Department of Neuroscience, Herestraat 49, Leuven 3000, Belgium
| | - Carmen Menacho Pando
- VIB Center for Brain and Disease Research, Herestraat 49, Leuven 3000, Belgium; KU Leuven Department of Neuroscience, Herestraat 49, Leuven 3000, Belgium
| | - Johann Urschitz
- Institute for Biogenesis Research, University of Hawaii, 1960 East-West Rd. E-124, Honolulu, HI 96822, USA
| | - Melvin Y Rincon
- VIB Center for Brain and Disease Research, Herestraat 49, Leuven 3000, Belgium; KU Leuven Department of Neuroscience, Herestraat 49, Leuven 3000, Belgium
| | - Stefan Moisyadi
- Institute for Biogenesis Research, University of Hawaii, 1960 East-West Rd. E-124, Honolulu, HI 96822, USA
| | - Frank Schnütgen
- Department of Medicine 2, University Hospital Frankfurt, Goethe University, Theodor Stern Kai 7, Frankfurt am Main D60590, Germany; LOEWE Center for Cell and Gene Therapy, University Hospital Frankfurt, Goethe University, Theodor Stern Kai 7, Frankfurt am Main D60590, Germany; FCI, Frankfurt Cancer Institute, University Hospital Frankfurt, Goethe University, Theodor Stern Kai 7, Frankfurt am Main D60590, Germany
| | - Hiroshi Kawasaki
- Department of Medical Neuroscience, Graduate School of Medicine, Kanazawa University, Ishikawa 920-1192, Japan
| | - Dietmar Schmucker
- VIB Center for Brain and Disease Research, Herestraat 49, Leuven 3000, Belgium; KU Leuven Department of Neuroscience, Herestraat 49, Leuven 3000, Belgium; Neuronal Wiring Group, Life & Medical Sciences Institute, University of Bonn, Carl-Troll-Straße 31, Bonn D53115, Germany; Leuven Brain Institute, Herestraat 49, Leuven 3000, Belgium.
| | - Matthew G Holt
- VIB Center for Brain and Disease Research, Herestraat 49, Leuven 3000, Belgium; KU Leuven Department of Neuroscience, Herestraat 49, Leuven 3000, Belgium; Leuven Brain Institute, Herestraat 49, Leuven 3000, Belgium; University of Porto, Instituto de Investigaçāo e Inovaçāo em Saúde (i3S), Rua Alfredo Allen 208, 4200-135 Porto, Portugal.
| |
Collapse
|
2
|
Edwards-Faret G, de Vin F, Slezak M, Gollenbeck L, Karaman R, Shinmyo Y, Batiuk MY, Pando CM, Urschitz J, Rincon MY, Moisyadi S, Schnütgen F, Kawasaki H, Schmucker D, Holt MG. Corrigendum to "A New Technical Approach for Cross-species Examination of Neuronal Wiring and Adult Neuron-glia Functions" [Neuroscience 508 (2023) 40-51. Neuroscience 2023:S0306-4522(23)00267-1. [PMID: 37355244 DOI: 10.1016/j.neuroscience.2023.06.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/26/2023]
Affiliation(s)
- Gabriela Edwards-Faret
- VIB Center for Brain and Disease Research, Herestraat 49, Leuven 3000, Belgium; KU Leuven Department of Neuroscience, Herestraat 49, Leuven 3000, Belgium; Neuronal Wiring Group, Life & Medical Sciences Institute, University of Bonn, Carl-Troll-Straße 31, Bonn D53115, Germany
| | - Filip de Vin
- VIB Center for Brain and Disease Research, Herestraat 49, Leuven 3000, Belgium; KU Leuven Department of Neuroscience, Herestraat 49, Leuven 3000, Belgium
| | - Michal Slezak
- VIB Center for Brain and Disease Research, Herestraat 49, Leuven 3000, Belgium; KU Leuven Department of Neuroscience, Herestraat 49, Leuven 3000, Belgium
| | - Lennart Gollenbeck
- Neuronal Wiring Group, Life & Medical Sciences Institute, University of Bonn, Carl-Troll-Straße 31, Bonn D53115, Germany
| | - Ruçhan Karaman
- VIB Center for Cancer Biology, Herestraat 49, Leuven 3000, Belgium; KU Leuven Department of Oncology, Herestraat 49, Leuven 3000, Belgium
| | - Yohei Shinmyo
- Department of Medical Neuroscience, Graduate School of Medicine, Kanazawa University, Ishikawa 920-1192, Japan
| | - Mykhailo Y Batiuk
- VIB Center for Brain and Disease Research, Herestraat 49, Leuven 3000, Belgium; KU Leuven Department of Neuroscience, Herestraat 49, Leuven 3000, Belgium
| | - Carmen Menacho Pando
- VIB Center for Brain and Disease Research, Herestraat 49, Leuven 3000, Belgium; KU Leuven Department of Neuroscience, Herestraat 49, Leuven 3000, Belgium
| | - Johann Urschitz
- Institute for Biogenesis Research, University of Hawaii, 1960 East-West Rd. E-124, Honolulu, HI 96822, USA
| | - Melvin Y Rincon
- VIB Center for Brain and Disease Research, Herestraat 49, Leuven 3000, Belgium; KU Leuven Department of Neuroscience, Herestraat 49, Leuven 3000, Belgium
| | - Stefan Moisyadi
- Institute for Biogenesis Research, University of Hawaii, 1960 East-West Rd. E-124, Honolulu, HI 96822, USA
| | - Frank Schnütgen
- Department of Medicine 2, University Hospital Frankfurt, Goethe University, Theodor Stern Kai 7, Frankfurt am Main D60590, Germany; LOEWE Center for Cell and Gene Therapy, University Hospital Frankfurt, Goethe University, Theodor Stern Kai 7, Frankfurt am Main D60590, Germany; FCI, Frankfurt Cancer Institute, University Hospital Frankfurt, Goethe University, Theodor Stern Kai 7, Frankfurt am Main D60590, Germany
| | - Hiroshi Kawasaki
- Department of Medical Neuroscience, Graduate School of Medicine, Kanazawa University, Ishikawa 920-1192, Japan
| | - Dietmar Schmucker
- VIB Center for Brain and Disease Research, Herestraat 49, Leuven 3000, Belgium; KU Leuven Department of Neuroscience, Herestraat 49, Leuven 3000, Belgium; Neuronal Wiring Group, Life & Medical Sciences Institute, University of Bonn, Carl-Troll-Straße 31, Bonn D53115, Germany; Leuven Brain Institute, Herestraat 49, Leuven 3000, Belgium.
| | - Matthew G Holt
- VIB Center for Brain and Disease Research, Herestraat 49, Leuven 3000, Belgium; KU Leuven Department of Neuroscience, Herestraat 49, Leuven 3000, Belgium; Leuven Brain Institute, Herestraat 49, Leuven 3000, Belgium; University of Porto, Instituto de Investigaçāo e Inovaçāo em Saúde (i3S), Rua Alfredo Allen 208, 4200-135 Porto, Portugal.
| |
Collapse
|
3
|
Edwards-Faret G, de Vin F, Slezak M, Gollenbeck L, Karaman R, Shinmyo Y, Batiuk MY, Pando CM, Urschitz J, Rincon MY, Moisyadi S, Schnütgen F, Kawasaki H, Schmucker D, Holt MG. A New Technical Approach for Cross-species Examination of Neuronal Wiring and Adult Neuron-glia Functions. Neuroscience 2023; 508:40-51. [PMID: 36464177 DOI: 10.1016/j.neuroscience.2022.11.029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2022] [Revised: 11/21/2022] [Accepted: 11/23/2022] [Indexed: 12/03/2022]
Abstract
Advances in single cell sequencing have enabled the identification of a large number of genes, expressed in many different cell types, and across a variety of model organisms. In particular, the nervous system harbors an immense number of interacting cell types, which are poorly characterized. Future loss- and gain-of-function experiments will be essential in determining how novel genes play critical roles in diverse cellular, as well as evolutionarily adapted, contexts. However, functional analysis across species is often hampered by technical limitations, in non-genetic animal systems. Here, we describe a new single plasmid system, misPiggy. The system is based around the hyperactive piggyBac transposon system, which combines stable genomic integration of transgenes (for long-term expression) with large cargo capacity. Taking full advantage of these characteristics, we engineered novel expression modules into misPiggy that allow for cell-type specific loss- and gain-of-gene function. These modules work widely across species from frog to ferret. As a proof of principle, we present a loss-of-function analysis of the neuronal receptor Deleted in Colorectal Cancer (DCC) in retinal ganglion cells (RGCs) of Xenopus tropicalis tadpoles. Single axon tracings of mosaic knock-out cells reveal a specific cell-intrinsic requirement of DCC, specifically in axonal arborization within the frog tectum, rather than retina-to-brain axon guidance. Furthermore, we report additional technical advances that enable temporal control of knock-down or gain-of-function analysis. We applied this to visualize and manipulate labeled neurons, astrocytes and other glial cells in the central nervous system (CNS) of mouse, rat and ferret. We propose that misPiggy will be a valuable tool for rapid, flexible and cost-effective screening of gene function across a variety of animal models.
Collapse
Affiliation(s)
- Gabriela Edwards-Faret
- VIB Center for Brain and Disease Research, Herestraat 49, Leuven 3000, Belgium; KU Leuven Department of Neuroscience, Herestraat 49, Leuven 3000, Belgium; Neuronal Wiring Group, Life & Medical Sciences Institute, University of Bonn, Carl-Troll-Straße 31, Bonn D53115, Germany
| | - Filip de Vin
- VIB Center for Brain and Disease Research, Herestraat 49, Leuven 3000, Belgium; KU Leuven Department of Neuroscience, Herestraat 49, Leuven 3000, Belgium
| | - Michal Slezak
- VIB Center for Brain and Disease Research, Herestraat 49, Leuven 3000, Belgium; KU Leuven Department of Neuroscience, Herestraat 49, Leuven 3000, Belgium
| | - Lennart Gollenbeck
- Neuronal Wiring Group, Life & Medical Sciences Institute, University of Bonn, Carl-Troll-Straße 31, Bonn D53115, Germany
| | - Ruçhan Karaman
- VIB Center for Cancer Biology, Herestraat 49, Leuven 3000, Belgium; KU Leuven Department of Oncology, Herestraat 49, Leuven 3000, Belgium
| | - Yohei Shinmyo
- Department of Medical Neuroscience, Graduate School of Medicine, Kanazawa University, Ishikawa 920-1192, Japan
| | - Mykhailo Y Batiuk
- VIB Center for Brain and Disease Research, Herestraat 49, Leuven 3000, Belgium; KU Leuven Department of Neuroscience, Herestraat 49, Leuven 3000, Belgium
| | - Carmen Menacho Pando
- VIB Center for Brain and Disease Research, Herestraat 49, Leuven 3000, Belgium; KU Leuven Department of Neuroscience, Herestraat 49, Leuven 3000, Belgium
| | - Johann Urschitz
- Institute for Biogenesis Research, University of Hawaii, 1960 East-West Rd. E-124, Honolulu, HI 96822, USA
| | - Melvin Y Rincon
- VIB Center for Brain and Disease Research, Herestraat 49, Leuven 3000, Belgium; KU Leuven Department of Neuroscience, Herestraat 49, Leuven 3000, Belgium
| | - Stefan Moisyadi
- Institute for Biogenesis Research, University of Hawaii, 1960 East-West Rd. E-124, Honolulu, HI 96822, USA
| | - Frank Schnütgen
- Department of Medicine 2, University Hospital Frankfurt, Goethe University, Theodor Stern Kai 7, Frankfurt am Main D60590, Germany; LOEWE Center for Cell and Gene Therapy, University Hospital Frankfurt, Goethe University, Theodor Stern Kai 7, Frankfurt am Main D60590, Germany; FCI, Frankfurt Cancer Institute, University Hospital Frankfurt, Goethe University, Theodor Stern Kai 7, Frankfurt am Main D60590, Germany
| | - Hiroshi Kawasaki
- Department of Medical Neuroscience, Graduate School of Medicine, Kanazawa University, Ishikawa 920-1192, Japan
| | - Dietmar Schmucker
- VIB Center for Brain and Disease Research, Herestraat 49, Leuven 3000, Belgium; KU Leuven Department of Neuroscience, Herestraat 49, Leuven 3000, Belgium; Neuronal Wiring Group, Life & Medical Sciences Institute, University of Bonn, Carl-Troll-Straße 31, Bonn D53115, Germany; Leuven Brain Institute, Herestraat 49, Leuven 3000, Belgium.
| | - Matthew G Holt
- VIB Center for Brain and Disease Research, Herestraat 49, Leuven 3000, Belgium; KU Leuven Department of Neuroscience, Herestraat 49, Leuven 3000, Belgium; Leuven Brain Institute, Herestraat 49, Leuven 3000, Belgium; University of Porto, Instituto de Investigaçāo e Inovaçāo em Saúde (i3S), Rua Alfredo Allen 208, 4200-135 Porto, Portugal.
| |
Collapse
|
4
|
Marino M, Zhou L, Rincon MY, Callaerts-Vegh Z, Verhaert J, Wahis J, Creemers E, Yshii L, Wierda K, Saito T, Marneffe C, Voytyuk I, Wouters Y, Dewilde M, Duqué SI, Vincke C, Levites Y, Golde TE, Saido TC, Muyldermans S, Liston A, De Strooper B, Holt MG. AAV-mediated delivery of an anti-BACE1 VHH alleviates pathology in an Alzheimer's disease model. EMBO Mol Med 2022; 14:e09824. [PMID: 35352880 PMCID: PMC8988209 DOI: 10.15252/emmm.201809824] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2019] [Revised: 02/11/2022] [Accepted: 02/14/2022] [Indexed: 01/18/2023] Open
Abstract
Single domain antibodies (VHHs) are potentially disruptive therapeutics, with important biological value for treatment of several diseases, including neurological disorders. However, VHHs have not been widely used in the central nervous system (CNS), largely because of their restricted blood-brain barrier (BBB) penetration. Here, we propose a gene transfer strategy based on BBB-crossing Adeno-associated virus (AAV)-based vectors to deliver VHH directly into the CNS. As a proof-of-concept, we explored the potential of AAV-delivered VHH to inhibit BACE1, a well-characterized target in Alzheimer's disease. First, we generated a panel of VHHs targeting BACE1, one of which, VHH-B9, shows high selectivity for BACE1 and efficacy in lowering BACE1 activity in vitro. We further demonstrate that a single systemic dose of AAV-VHH-B9 produces positive long-term (12 months plus) effects on amyloid load, neuroinflammation, synaptic function, and cognitive performance, in the AppNL-G-F Alzheimer's disease mouse model. These results constitute a novel therapeutic approach forneurodegenerative diseases, which is applicable to a range of CNS disease targets.
Collapse
Affiliation(s)
- Marika Marino
- VIB-KU Leuven Center for Brain and Disease Research, Leuven, Belgium.,Department of Neurosciences, KU Leuven, Leuven, Belgium
| | - Lujia Zhou
- VIB-KU Leuven Center for Brain and Disease Research, Leuven, Belgium.,Department of Neurosciences, KU Leuven, Leuven, Belgium
| | - Melvin Y Rincon
- VIB-KU Leuven Center for Brain and Disease Research, Leuven, Belgium.,Department of Neurosciences, KU Leuven, Leuven, Belgium
| | | | - Jens Verhaert
- VIB-KU Leuven Center for Brain and Disease Research, Leuven, Belgium.,Department of Neurosciences, KU Leuven, Leuven, Belgium
| | - Jérôme Wahis
- VIB-KU Leuven Center for Brain and Disease Research, Leuven, Belgium.,Department of Neurosciences, KU Leuven, Leuven, Belgium
| | - Eline Creemers
- VIB-KU Leuven Center for Brain and Disease Research, Leuven, Belgium.,Department of Neurosciences, KU Leuven, Leuven, Belgium.,Electrophysiology Expertise Unit, VIB-KU Leuven Center for Brain and Disease Research, Leuven, Belgium
| | - Lidia Yshii
- VIB-KU Leuven Center for Brain and Disease Research, Leuven, Belgium.,Department of Neurosciences, KU Leuven, Leuven, Belgium.,Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium
| | - Keimpe Wierda
- VIB-KU Leuven Center for Brain and Disease Research, Leuven, Belgium.,Department of Neurosciences, KU Leuven, Leuven, Belgium.,Electrophysiology Expertise Unit, VIB-KU Leuven Center for Brain and Disease Research, Leuven, Belgium
| | - Takashi Saito
- Department of Neurocognitive Science, Institute of Brain Science, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
| | - Catherine Marneffe
- VIB-KU Leuven Center for Brain and Disease Research, Leuven, Belgium.,Department of Neurosciences, KU Leuven, Leuven, Belgium
| | - Iryna Voytyuk
- VIB-KU Leuven Center for Brain and Disease Research, Leuven, Belgium.,Department of Neurosciences, KU Leuven, Leuven, Belgium
| | - Yessica Wouters
- VIB-KU Leuven Center for Brain and Disease Research, Leuven, Belgium.,Department of Neurosciences, KU Leuven, Leuven, Belgium
| | - Maarten Dewilde
- VIB-KU Leuven Center for Brain and Disease Research, Leuven, Belgium.,Department of Neurosciences, KU Leuven, Leuven, Belgium
| | - Sandra I Duqué
- VIB-KU Leuven Center for Brain and Disease Research, Leuven, Belgium.,Department of Neurosciences, KU Leuven, Leuven, Belgium
| | - Cécile Vincke
- Laboratory of Cellular and Molecular Immunology, Vrije Universiteit Brussel, Brussels, Belgium
| | - Yona Levites
- Department of Neuroscience, Center for Translational Research in Neurodegenerative Disease, McKnight Brain Institute, College of Medicine, University of Florida, Gainesville, FL, USA
| | - Todd E Golde
- Department of Neuroscience, Center for Translational Research in Neurodegenerative Disease, McKnight Brain Institute, College of Medicine, University of Florida, Gainesville, FL, USA
| | - Takaomi C Saido
- Laboratory for Proteolytic Neuroscience, RIKEN Brain Science Institute, Wako-shi, Japan
| | - Serge Muyldermans
- Laboratory of Cellular and Molecular Immunology, Vrije Universiteit Brussel, Brussels, Belgium
| | - Adrian Liston
- VIB-KU Leuven Center for Brain and Disease Research, Leuven, Belgium.,Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium.,Immunology Programme, The Babraham Institute, Cambridge, UK
| | - Bart De Strooper
- VIB-KU Leuven Center for Brain and Disease Research, Leuven, Belgium.,Department of Neurosciences, KU Leuven, Leuven, Belgium.,UK Dementia Research institute at UCL, London, UK.,Leuven Brain Institute, Leuven, Belgium
| | - Matthew G Holt
- VIB-KU Leuven Center for Brain and Disease Research, Leuven, Belgium.,Department of Neurosciences, KU Leuven, Leuven, Belgium.,Leuven Brain Institute, Leuven, Belgium.,Instituto de Investigação e Inovação em Saúde (i3S), University of Porto, Porto, Portugal
| |
Collapse
|
5
|
Sánchez-Villamil JP, Bautista-Niño PK, Serrano NC, Rincon MY, Garg NJ. Potential Role of Antioxidants as Adjunctive Therapy in Chagas Disease. Oxid Med Cell Longev 2020; 2020:9081813. [PMID: 32308809 PMCID: PMC7136780 DOI: 10.1155/2020/9081813] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 12/19/2019] [Revised: 03/02/2020] [Accepted: 03/07/2020] [Indexed: 02/07/2023]
Abstract
Chagas disease (CD) is one of the most important neglected tropical diseases in the American continent. Host-derived nitroxidative stress in response to Trypanosoma cruzi infection can induce tissue damage contributing to the progression of Chagas disease. Antioxidant supplementation has been suggested as adjuvant therapy to current treatment. In this article, we synthesize and discuss the current evidence regarding the use of antioxidants as adjunctive compounds to fight harmful reactive oxygen species and lower the tissue oxidative damage during progression of chronic Chagas disease. Several antioxidants evaluated in recent studies have shown potential benefits for the control of oxidative stress in the host's tissues. Melatonin, resveratrol, the combination of vitamin C/vitamin E (vitC/vitE) or curcumin/benznidazole, and mitochondria-targeted antioxidants seem to be beneficial in reducing plasma and cardiac levels of lipid peroxidation products. Nevertheless, further research is needed to validate beneficial effects of antioxidant therapies in Chagas disease.
Collapse
Affiliation(s)
- Juana P. Sánchez-Villamil
- Translational Biomedical Research Group, Centro de Investigaciones, Fundación Cardiovascular de Colombia, Santander, Colombia
- Faculty of Basic Sciences, Universidad Antonio Nariño, Santander, Colombia
| | - Paula K. Bautista-Niño
- Translational Biomedical Research Group, Centro de Investigaciones, Fundación Cardiovascular de Colombia, Santander, Colombia
| | - Norma C. Serrano
- Translational Biomedical Research Group, Centro de Investigaciones, Fundación Cardiovascular de Colombia, Santander, Colombia
| | - Melvin Y. Rincon
- Translational Biomedical Research Group, Centro de Investigaciones, Fundación Cardiovascular de Colombia, Santander, Colombia
| | - Nisha J. Garg
- Department of Microbiology and Immunology, Institute for Human Infections and Immunity, University of Texas Medical Branch, Galveston, Texas, USA
| |
Collapse
|
6
|
Gonzalez-Ortiz LM, Sanchez-Villamil JP, Celis-Rodriguez MA, Lineros G, Sanabria-Barrera S, Serrano NC, Rincon MY, Bautista-Nino PK. Measuring mitochondrial respiration in adherent cells infected with Trypanosoma cruzi Chagas, 1909 using Seahorse extracellular flux analyser. Folia Parasitol (Praha) 2019; 66. [PMID: 31631068 DOI: 10.14411/fp.2019.016] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2019] [Accepted: 05/06/2019] [Indexed: 11/19/2022]
Abstract
Infection with Trypanosoma cruzi Chagas, 1909 is reported to increase the production of reactive oxygen species in patients with Chagas disease. Mitochondria dysfunction, host inflammatory response and inadequate antioxidant response are described as the main factors leading to oxidative stress during acute and chronic stages of the disease. The Seahorse XFe24 extracellular flux platform allows energy metabolism determination through mitochondrial respiration and glycolysis measurements. XFe24 platform can be used in in vitro models of T. cruzi-infected cells, which allow the assessment and even modulation of endogenous conditions of infected cells, generating readouts of real-time cellular bioenergetics changes. In this protocol, we standardised the use of XFe24 technology in T. cruzi infected AC16 cardiomyocytes and SGHPL-5 trophoblasts. In addition, we provide a list of optimised assay specifications, advantages and critical steps to be considered during the process. Cardiomyocytes and trophoblasts are attractive target cells to evaluate the metabolic environment in acute, chronic and congenital Chagas transmission scenarios.
Collapse
Affiliation(s)
- Laura Maria Gonzalez-Ortiz
- Traslational Biomedical Research Group, Centro de Investigaciones, Fundacion Cardiovascular de Colombia, Santander, Colombia
| | - Juana Patricia Sanchez-Villamil
- Traslational Biomedical Research Group, Centro de Investigaciones, Fundacion Cardiovascular de Colombia, Santander, Colombia
| | - Mike A Celis-Rodriguez
- Traslational Biomedical Research Group, Centro de Investigaciones, Fundacion Cardiovascular de Colombia, Santander, Colombia
| | - Giovanni Lineros
- Traslational Biomedical Research Group, Centro de Investigaciones, Fundacion Cardiovascular de Colombia, Santander, Colombia
| | - Sandra Sanabria-Barrera
- Traslational Biomedical Research Group, Centro de Investigaciones, Fundacion Cardiovascular de Colombia, Santander, Colombia
| | - Norma C Serrano
- Traslational Biomedical Research Group, Centro de Investigaciones, Fundacion Cardiovascular de Colombia, Santander, Colombia
| | - Melvin Y Rincon
- Traslational Biomedical Research Group, Centro de Investigaciones, Fundacion Cardiovascular de Colombia, Santander, Colombia
| | - Paula K Bautista-Nino
- Traslational Biomedical Research Group, Centro de Investigaciones, Fundacion Cardiovascular de Colombia, Santander, Colombia
| |
Collapse
|
7
|
Fripont S, Marneffe C, Marino M, Rincon MY, Holt MG. Production, Purification, and Quality Control for Adeno-associated Virus-based Vectors. J Vis Exp 2019. [DOI: 10.3791/58960] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022] Open
|
8
|
Sierra-Delgado JA, Bautista-Nino PK, Vargas-Castellanos CI, Serrano Diaz NC, Rincon MY. [Immune response and gene therapy with adenoassociated viral vectors]. Medicina (B Aires) 2019; 79:493-501. [PMID: 31829952] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/10/2023] Open
Abstract
In recent years, gene therapy has been positioned as a real and safe option in the development of therapeutic alternatives for the cure and prevention of different diseases. It consists in the insertion of genetic material in a defective tissue or cell, through the use of a vector. There are several considerations for selecting the most appropriate vector, including the potential for binding and entry to the target cell, the ability of the genetic material to transfer to the nucleus, the ability to express the insert, and the absence of toxicity. In the current scenario, the most commonly used viral vectors are those derived from adeno-associated viruses (AAV). Characteristics such as biosafety, low toxicity and selective tropism have enabled its evaluation as a therapeutic option in many monogenic or complex diseases. Despite their advantages, AAV vectors have drawbacks, the most important being the patient's immune response to the vector, especially the response mediated by neutralizing antibodies (NAb). NAbs decrease the transduction of the vector and prevent the expression of the gene it transports, limiting its clinical application. Therefore, identifying and quantifying the presence and activity of NAbs is the first step in any gene therapy protocol with AAV vectors. The presence of NAbs depends mainly on exposure to the virus in nature and varies drastically according to age, geographic location and health status of the person evaluated.
Collapse
Affiliation(s)
- Julieth A Sierra-Delgado
- Universidad Industrial de Santander, Bucaramanga, Santander, Colombia
- Dirección de Investigaciones, Fundación Cardiovascular de Colombia, Floridablanca, Santander, Colombia
| | - Paula K Bautista-Nino
- Dirección de Investigaciones, Fundación Cardiovascular de Colombia, Floridablanca, Santander, Colombia
| | | | - Norma C Serrano Diaz
- Dirección de Investigaciones, Fundación Cardiovascular de Colombia, Floridablanca, Santander, Colombia
- Hospital Internacional de Colombia, Piedecuesta, Santander, Colombia
| | - Melvin Y Rincon
- Dirección de Investigaciones, Fundación Cardiovascular de Colombia, Floridablanca, Santander, Colombia. E-mail:
| |
Collapse
|
9
|
Rincon MY, de Vin F, Duqué SI, Fripont S, Castaldo SA, Bouhuijzen-Wenger J, Holt MG. Widespread transduction of astrocytes and neurons in the mouse central nervous system after systemic delivery of a self-complementary AAV-PHP.B vector. Gene Ther 2018. [PMID: 29523880 DOI: 10.1038/s41434-018-0005-z] [Citation(s) in RCA: 32] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
Abstract
Until recently, adeno-associated virus 9 (AAV9) was considered the AAV serotype most effective in crossing the blood-brain barrier (BBB) and transducing cells of the central nervous system (CNS), following systemic injection. However, a newly engineered capsid, AAV-PHP.B, is reported to cross the BBB at even higher efficiency. We investigated how much we could boost CNS transgene expression by using AAV-PHP.B carrying a self-complementary (sc) genome. To allow comparison, 6 weeks old C57BL/6 mice received intravenous injections of scAAV2/9-GFP or scAAV2/PHP.B-GFP at equivalent doses. Three weeks postinjection, transgene expression was assessed in brain and spinal cord. We consistently observed more widespread CNS transduction and higher levels of transgene expression when using the scAAV2/PHP.B-GFP vector. In particular, we observed an unprecedented level of astrocyte transduction in the cortex, when using a ubiquitous CBA promoter. In comparison, neuronal transduction was much lower than previously reported. However, strong neuronal expression (including spinal motor neurons) was observed when the human synapsin promoter was used. These findings constitute the first reported use of an AAV-PHP.B capsid, encapsulating a scAAV genome, for gene transfer in adult mice. Our results underscore the potential of this AAV construct as a platform for safer and more efficacious gene therapy vectors for the CNS.
Collapse
Affiliation(s)
- Melvin Y Rincon
- VIB-KU Leuven Center for Brain & Disease Research, Leuven, Belgium.,KU Leuven, Department of Neuroscience, Leuven, Belgium
| | - Filip de Vin
- VIB-KU Leuven Center for Brain & Disease Research, Leuven, Belgium.,KU Leuven, Department of Neuroscience, Leuven, Belgium
| | - Sandra I Duqué
- VIB-KU Leuven Center for Brain & Disease Research, Leuven, Belgium.,KU Leuven, Department of Neuroscience, Leuven, Belgium
| | - Shelly Fripont
- VIB-KU Leuven Center for Brain & Disease Research, Leuven, Belgium.,KU Leuven, Department of Neuroscience, Leuven, Belgium
| | - Stephanie A Castaldo
- VIB-KU Leuven Center for Cancer Biology, Leuven, Belgium.,KU Leuven, Department of Oncology, Leuven, Belgium
| | - Jessica Bouhuijzen-Wenger
- VIB-KU Leuven Center for Brain & Disease Research, Leuven, Belgium.,KU Leuven, Department of Neuroscience, Leuven, Belgium
| | - Matthew G Holt
- VIB-KU Leuven Center for Brain & Disease Research, Leuven, Belgium. .,KU Leuven, Department of Neuroscience, Leuven, Belgium.
| |
Collapse
|
10
|
Rincon MY, Prada CE, Lopez M, Castillo V, Echeverria LE, Serrano N. Determination of Anti-Adeno-Associated Viral Vector Neutralizing Antibodies in Patients With Heart Failure in the Cardiovascular Foundation of Colombia (ANVIAS): Study Protocol. JMIR Res Protoc 2016; 5:e102. [PMID: 27282359 PMCID: PMC4919550 DOI: 10.2196/resprot.5535] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2016] [Revised: 03/22/2016] [Accepted: 04/04/2016] [Indexed: 01/03/2023] Open
Abstract
Background Recent progress in the pathophysiology of heart failure (HF) has led to the development of new therapeutic options such as gene therapy and the use of adeno-associated viral (AAV) vectors. Despite the promising results in early clinical trials of gene therapy for HF, various obstacles have been faced, such as the presence of neutralizing antibodies (NAbs) against the capsid vectors. NAb activity limits vector transduction levels and therefore diminishes the final therapeutic response. Recent studies evaluating the prevalence of NAbs in various populations found considerable geographic variability for each AAV serotype. However, the levels of NAbs in Latin American populations are unknown, becoming a limiting factor to conducting AAV vector therapeutic trials in this population. Objective The goal of this study is to determine for the first time, the prevalence of anti-AAV NAbs for the serotypes 1, 2, and 9 in HF patients from the city of Bucaramanga, Colombia, using the in vitro transduction inhibition assay. Methods We will conduct a cross-sectional study with patients who periodically attend the HF clinic of the Cardiovascular Foundation of Colombia and healthy volunteers matched for age and sex. For all participants, we will evaluate the NAb levels against serotypes AAV1, AAV2, and AAV9. We will determine NAb levels using the in vitro transduction inhibition assay. In addition, participants will answer a survey to evaluate their epidemiological and socioeconomic variables. Participation in the study will be voluntary and all participants will sign an informed consent document before any intervention. Results The project is in the first phase: elaboration of case report forms and the informed consent form, and design of the recruitment strategy. Patient recruitment is expected to begin in the spring of 2016. We expect to have preliminary results, including the titer of the viral vectors, multiplicity of infections that we will use for each serotype, and the general validation of the assay, at the end of 2016. The final results are expected mid-2017. Conclusions This project is the first effort to evaluate NAb levels against AAV1, AAV2, and AAV9 serotypes in patients with HF in Latin America. Our results will allow us to check the cross-reactivity response between the serotypes assessed, to describe the epidemiological characteristics of the participant population, and to set up a link with earlier reports of NAb prevalence in the literature.
Collapse
Affiliation(s)
- Melvin Y Rincon
- Centro de Investigaciones, Fundacion Cardiovascular de Colombia, Floridablanca, Colombia.
| | | | | | | | | | | |
Collapse
|
11
|
Rincon MY, VandenDriessche T, Chuah MK. Gene therapy for cardiovascular disease: advances in vector development, targeting, and delivery for clinical translation. Cardiovasc Res 2015; 108:4-20. [PMID: 26239654 PMCID: PMC4571836 DOI: 10.1093/cvr/cvv205] [Citation(s) in RCA: 107] [Impact Index Per Article: 11.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/13/2015] [Accepted: 07/22/2015] [Indexed: 01/06/2023] Open
Abstract
Gene therapy is a promising modality for the treatment of inherited and acquired cardiovascular diseases. The identification of the molecular pathways involved in the pathophysiology of heart failure and other associated cardiac diseases led to encouraging preclinical gene therapy studies in small and large animal models. However, the initial clinical results yielded only modest or no improvement in clinical endpoints. The presence of neutralizing antibodies and cellular immune responses directed against the viral vector and/or the gene-modified cells, the insufficient gene expression levels, and the limited gene transduction efficiencies accounted for the overall limited clinical improvements. Nevertheless, further improvements of the gene delivery technology and a better understanding of the underlying biology fostered renewed interest in gene therapy for heart failure. In particular, improved vectors based on emerging cardiotropic serotypes of the adeno-associated viral vector (AAV) are particularly well suited to coax expression of therapeutic genes in the heart. This led to new clinical trials based on the delivery of the sarcoplasmic reticulum Ca2+-ATPase protein (SERCA2a). Though the first clinical results were encouraging, a recent Phase IIb trial did not confirm the beneficial clinical outcomes that were initially reported. New approaches based on S100A1 and adenylate cyclase 6 are also being considered for clinical applications. Emerging paradigms based on the use of miRNA regulation or CRISPR/Cas9-based genome engineering open new therapeutic perspectives for treating cardiovascular diseases by gene therapy. Nevertheless, the continuous improvement of cardiac gene delivery is needed to allow the use of safer and more effective vector doses, ultimately bringing gene therapy for heart failure one step closer to reality.
Collapse
Affiliation(s)
- Melvin Y Rincon
- Department of Gene Therapy and Regenerative Medicine, Free University of Brussels (VUB), Building D, room D306, Laarbeeklaan 103, Brussels, Belgium Centro de Investigaciones, Fundacion Cardiovascular de Colombia, Floridablanca, Colombia
| | - Thierry VandenDriessche
- Department of Gene Therapy and Regenerative Medicine, Free University of Brussels (VUB), Building D, room D306, Laarbeeklaan 103, Brussels, Belgium Center for Molecular and Vascular Biology, Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium
| | - Marinee K Chuah
- Department of Gene Therapy and Regenerative Medicine, Free University of Brussels (VUB), Building D, room D306, Laarbeeklaan 103, Brussels, Belgium Center for Molecular and Vascular Biology, Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium
| |
Collapse
|
12
|
Rincon MY, Sarcar S, Danso-Abeam D, Keyaerts M, Matrai J, Samara-Kuko E, Acosta-Sanchez A, Athanasopoulos T, Dickson G, Lahoutte T, De Bleser P, VandenDriessche T, Chuah MK. Genome-wide computational analysis reveals cardiomyocyte-specific transcriptional Cis-regulatory motifs that enable efficient cardiac gene therapy. Mol Ther 2015; 23:43-52. [PMID: 25195597 PMCID: PMC4426801 DOI: 10.1038/mt.2014.178] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2014] [Accepted: 08/29/2014] [Indexed: 12/19/2022] Open
Abstract
Gene therapy is a promising emerging therapeutic modality for the treatment of cardiovascular diseases and hereditary diseases that afflict the heart. Hence, there is a need to develop robust cardiac-specific expression modules that allow for stable expression of the gene of interest in cardiomyocytes. We therefore explored a new approach based on a genome-wide bioinformatics strategy that revealed novel cardiac-specific cis-acting regulatory modules (CS-CRMs). These transcriptional modules contained evolutionary-conserved clusters of putative transcription factor binding sites that correspond to a "molecular signature" associated with robust gene expression in the heart. We then validated these CS-CRMs in vivo using an adeno-associated viral vector serotype 9 that drives a reporter gene from a quintessential cardiac-specific α-myosin heavy chain promoter. Most de novo designed CS-CRMs resulted in a >10-fold increase in cardiac gene expression. The most robust CRMs enhanced cardiac-specific transcription 70- to 100-fold. Expression was sustained and restricted to cardiomyocytes. We then combined the most potent CS-CRM4 with a synthetic heart and muscle-specific promoter (SPc5-12) and obtained a significant 20-fold increase in cardiac gene expression compared to the cytomegalovirus promoter. This study underscores the potential of rational vector design to improve the robustness of cardiac gene therapy.
Collapse
Affiliation(s)
- Melvin Y Rincon
- Department of Gene Therapy & Regenerative Medicine, Free University of Brussels (VUB), Brussels, Belgium
- Center for Molecular & Vascular Biology, Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium
| | - Shilpita Sarcar
- Department of Gene Therapy & Regenerative Medicine, Free University of Brussels (VUB), Brussels, Belgium
| | - Dina Danso-Abeam
- Center for Molecular & Vascular Biology, Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium
| | - Marleen Keyaerts
- Nuclear Medicine Department, UZ Brussel & In vivo Cellular and Molecular Imaging Lab, Free University of Brussels (VUB), Brussels, Belgium
| | - Janka Matrai
- Department of Gene Therapy & Regenerative Medicine, Free University of Brussels (VUB), Brussels, Belgium
- Center for Molecular & Vascular Biology, Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium
| | - Ermira Samara-Kuko
- Department of Gene Therapy & Regenerative Medicine, Free University of Brussels (VUB), Brussels, Belgium
- Center for Molecular & Vascular Biology, Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium
| | - Abel Acosta-Sanchez
- Vesalius Research Center, Flanders Institute of Biotechnology (VIB) & University of Leuven, Leuven, Belgium
| | | | - George Dickson
- School of Biological Sciences, Royal Holloway - University of London, Egham, UK
| | - Tony Lahoutte
- Nuclear Medicine Department, UZ Brussel & In vivo Cellular and Molecular Imaging Lab, Free University of Brussels (VUB), Brussels, Belgium
| | - Pieter De Bleser
- Inflammation Research Center, Flanders Institute of Biotechnology (VIB) and Department of Biomedical Molecular Biology, Ghent University, Ghent, Belgium
| | - Thierry VandenDriessche
- Department of Gene Therapy & Regenerative Medicine, Free University of Brussels (VUB), Brussels, Belgium
- Center for Molecular & Vascular Biology, Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium
| | - Marinee K Chuah
- Department of Gene Therapy & Regenerative Medicine, Free University of Brussels (VUB), Brussels, Belgium
- Center for Molecular & Vascular Biology, Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium
| |
Collapse
|
13
|
Chuah MK, Petrus I, De Bleser P, Le Guiner C, Gernoux G, Adjali O, Nair N, Willems J, Evens H, Rincon MY, Matrai J, Di Matteo M, Samara-Kuko E, Yan B, Acosta-Sanchez A, Meliani A, Cherel G, Blouin V, Christophe O, Moullier P, Mingozzi F, VandenDriessche T. Liver-specific transcriptional modules identified by genome-wide in silico analysis enable efficient gene therapy in mice and non-human primates. Mol Ther 2014; 22:1605-13. [PMID: 24954473 PMCID: PMC4435486 DOI: 10.1038/mt.2014.114] [Citation(s) in RCA: 63] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2014] [Accepted: 06/09/2014] [Indexed: 12/18/2022] Open
Abstract
The robustness and safety of liver-directed gene therapy can be substantially
improved by enhancing expression of the therapeutic transgene in the liver. To
achieve this, we developed a new approach of rational in silico vector
design. This approach relies on a genome-wide bio-informatics strategy to
identify cis-acting regulatory modules (CRMs) containing
evolutionary conserved clusters of transcription factor binding site motifs that
determine high tissue-specific gene expression. Incorporation of these
CRMs into adeno-associated viral (AAV) and non-viral vectors
enhanced gene expression in mice liver 10 to 100-fold, depending on the promoter
used. Furthermore, these CRMs resulted in robust and sustained
liver-specific expression of coagulation factor IX (FIX), validating their
immediate therapeutic and translational relevance. Subsequent translational
studies indicated that therapeutic FIX expression levels could be attained
reaching 20–35% of normal levels after AAV-based liver-directed gene
therapy in cynomolgus macaques. This study underscores the potential of rational
vector design using computational approaches to improve their robustness and
therefore allows for the use of lower and thus safer vector doses for gene
therapy, while maximizing therapeutic efficacy.
Collapse
Affiliation(s)
- Marinee K Chuah
- 1] Department of Gene Therapy & Regenerative Medicine, Free University of Brussels (VUB), Brussels, Belgium [2] Department of Cardiovascular Sciences, Center for Molecular & Vascular Biology, University of Leuven, Leuven, Belgium
| | - Inge Petrus
- Department of Cardiovascular Sciences, Center for Molecular & Vascular Biology, University of Leuven, Leuven, Belgium
| | - Pieter De Bleser
- Department for Molecular Biomedical Research (DMBR), VIB - Ghent University, Ghent, Belgium
| | - Caroline Le Guiner
- 1] INSERM UMR 1089, Atlantic Gene Therapies, Université de Nantes, Nantes, France [2] CHU de Nantes, Nantes, France
| | - Gwladys Gernoux
- 1] INSERM UMR 1089, Atlantic Gene Therapies, Université de Nantes, Nantes, France [2] CHU de Nantes, Nantes, France
| | - Oumeya Adjali
- 1] INSERM UMR 1089, Atlantic Gene Therapies, Université de Nantes, Nantes, France [2] CHU de Nantes, Nantes, France
| | - Nisha Nair
- Department of Gene Therapy & Regenerative Medicine, Free University of Brussels (VUB), Brussels, Belgium
| | - Jessica Willems
- Department of Gene Therapy & Regenerative Medicine, Free University of Brussels (VUB), Brussels, Belgium
| | - Hanneke Evens
- Department of Gene Therapy & Regenerative Medicine, Free University of Brussels (VUB), Brussels, Belgium
| | - Melvin Y Rincon
- 1] Department of Gene Therapy & Regenerative Medicine, Free University of Brussels (VUB), Brussels, Belgium [2] Department of Cardiovascular Sciences, Center for Molecular & Vascular Biology, University of Leuven, Leuven, Belgium
| | - Janka Matrai
- 1] Department of Gene Therapy & Regenerative Medicine, Free University of Brussels (VUB), Brussels, Belgium [2] Vesalius Research Center, VIB, Leuven, Belgium [3] University of Leuven, Leuven, Belgium
| | - Mario Di Matteo
- 1] Department of Gene Therapy & Regenerative Medicine, Free University of Brussels (VUB), Brussels, Belgium [2] Department of Cardiovascular Sciences, Center for Molecular & Vascular Biology, University of Leuven, Leuven, Belgium
| | - Ermira Samara-Kuko
- Department of Gene Therapy & Regenerative Medicine, Free University of Brussels (VUB), Brussels, Belgium
| | - Bing Yan
- 1] Vesalius Research Center, VIB, Leuven, Belgium [2] University of Leuven, Leuven, Belgium
| | - Abel Acosta-Sanchez
- 1] Vesalius Research Center, VIB, Leuven, Belgium [2] University of Leuven, Leuven, Belgium
| | - Amine Meliani
- 1] Genethon, Evry, France [2] University Pierre and Marie Curie, Paris, France
| | - Ghislaine Cherel
- 1] INSERM, U770, Le Kremlin Bicêtre, France [2] Université Paris-Sud, Le Kremlin Bicêtre, France
| | - Véronique Blouin
- 1] INSERM UMR 1089, Atlantic Gene Therapies, Université de Nantes, Nantes, France [2] CHU de Nantes, Nantes, France
| | - Olivier Christophe
- 1] INSERM, U770, Le Kremlin Bicêtre, France [2] Université Paris-Sud, Le Kremlin Bicêtre, France
| | - Philippe Moullier
- 1] INSERM UMR 1089, Atlantic Gene Therapies, Université de Nantes, Nantes, France [2] CHU de Nantes, Nantes, France
| | - Federico Mingozzi
- 1] Genethon, Evry, France [2] University Pierre and Marie Curie, Paris, France
| | - Thierry VandenDriessche
- 1] Department of Gene Therapy & Regenerative Medicine, Free University of Brussels (VUB), Brussels, Belgium [2] Department of Cardiovascular Sciences, Center for Molecular & Vascular Biology, University of Leuven, Leuven, Belgium
| |
Collapse
|
14
|
Abstract
Preeclampsia (PE) is a major cause of maternal and perinatal mortality, especially in developing countries. Its etiology involves multiple factors, but no specific cause has been identified. Evidence suggests that clinical manifestations are caused by endothelial dysfunction. Nitric oxide (NO), which is synthesized from L-arginine in endothelial cells by the endothelial nitric oxide synthase (eNOS), provides a tonic dilator tone and regulates the adhesion of white blood cells and platelet aggregation. Alterations in the L-arginine-NO pathway have been associated with the development of PE. Various studies, reporting decreased, elevated or unchanged levels of nitrite (NO(2)) and nitrate (NO(3)), two end products of NO metabolism, have been published. Our group contributed to those contradictory reports describing cases of PE with both elevated and decreased levels of NO(2) and NO(3). Apparently, diminished levels of NO could be related to deficiencies in the ingestion of dietary calcium associated to low levels of plasma ionic calcium, which is crucial to the eNOS' activity. Also, low levels of NO could be associated with the presence of eNOS polymorphisms or the presence of increased levels of ADMA, the endogenous inhibitor of NO. High levels of NO associated to low levels of cGMP suggest a decreased bioactivity of NO, which is probably related to an increased degradation of NO caused by a high production of superoxide in states of infection and inflammation. The present article analyses and reviews the reported paradoxical roles of the L-arginine-NO pathway in PE and gives a possible explanation for these results.
Collapse
Affiliation(s)
- Patricio López-Jaramillo
- VILANO Group, Research Institute, Fundación Cardiovascular de Colombia, Floridablanca, Santander, Colombia.
| | | | | | | | | |
Collapse
|